Jci_page_head_homepage_01 Jci_page_head_homepage_02
Steven Grant
Published in Volume 118, Issue 10
J Clin Invest. 2008; 118(10):3513 doi:10.1172/JCI36898E1
Full text | PDF
Citation information

Total citations by year in CrossRef

Year: 2012 2011 2010 2009 Total
Citations: 2 1 3 6 12

Citations to this article in CrossRef (12)

Title and authors Publication Year
miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-κB factor in human fibrosarcoma cells
Michael J. Wilson, Ping Liu
J. Cell. Physiol. 2012
Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein Kinase (MAPK) and Phosphatidylinositol-3-kinase (PI3K)/AKT pathways
Jun-ichi Hanai, Nathaniel Doro, Atsuo T. Sasaki, Susumu Kobayashi, Lewis C. Cantley, Pankaj Seth, Vikas P. Sukhatme
J. Cell. Physiol. 2012
ERK2 is essential for the growth of human epithelioid malignant mesotheliomas
Arti Shukla, Jedd M. Hillegass, Maximilian B. MacPherson, Stacie L. Beuschel, Pamela M. Vacek, Kelly J. Butnor, Harvey I. Pass, Michele Carbone, Joseph R. Testa, Nicholas H. Heintz, Brooke T. Mossman
Int. J. Cancer 2011
RSK in tumorigenesis: connections to steroid signaling.
T S Karin Eisinger-Mathason, Josefa Andrade, Deborah A Lannigan
Steroids 2010
Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244
Sylwia Ammoun, Natalia Ristic, Cordula Matthies, David A. Hilton, C. Oliver Hanemann
Neurobiology of Disease 2010
Compensatory activation of Akt in response to mTOR and Raf inhibitors – A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
Kathrin Zitzmann, Janina von Rüden, Stephan Brand, Burkhard Göke, Jennifer Lichtl, Gerald Spöttl, Christoph J. Auernhammer
Cancer Letters 2010
Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.
Paul Dent, David T Curiel, Paul B Fisher, Steven Grant
Drug Resist. Updat. 2009
New agents for AML and MDS.
Steven Grant
Best Pract Res Clin Haematol 2009
Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.
Peter W Schlosshauer, Wei Li, Kai-Ti Lin, Joseph L-K Chan, Lu-Hai Wang
Gynecologic Oncology 2009
Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/β-catenin signaling
Chandra P. Prasad, Gayatri Rath, Sandeep Mathur, Dinesh Bhatnagar, Ranju Ralhan
Chemico-Biological Interactions 2009